SLC5A2 and cardiovascular disorder: It should be considered hypothesis generating until dedicated RCTs or patient-level meta-analyses are conducted to prove causality and elucidate the specific mechanism of action of SGLT2 inhibitors in influencing the different pathways leading to AF in different cardiovascular diseases.